No, it's contingent on what exactly the classifier does and how independent of third party clinical judgement it is. The more hands off the clinician is, the more dangerous a false negative is, and the more time sensitive the result is, the more likely your diagnostic is going to be class 3.

I would naively expect the bulk of new low risk ML product submissions to be de Novo submissions due to lack of real precedent.